Rigel Pharmaceuticals ( (RIGL) ) has released its Q1 earnings. Here is a breakdown of the information Rigel Pharmaceuticals presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rigel Pharmaceuticals is a biotechnology company focused on developing novel therapies for hematologic disorders and cancer, with products like TAVALISSE and REZLIDHIA approved by the FDA. In its latest earnings report for the quarter ending March 31, 2025, Rigel Pharmaceuticals reported significant financial growth, highlighted by a net income of $11.4 million compared to a net loss of $8.2 million in the same quarter last year. The company’s total revenues increased to $53.3 million from $29.5 million, driven by strong product sales and collaboration revenues. Key financial metrics include a rise in product sales to $43.6 million and a notable increase in contract revenues from collaborations to $9.8 million. Rigel also reported a positive cash position with $77.1 million in cash, cash equivalents, and short-term investments. Looking ahead, Rigel Pharmaceuticals remains focused on advancing its pipeline and leveraging strategic partnerships to sustain its growth trajectory.